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Metastasis of primary tumors leads to a very poor prognosis for
patients suffering from cancer. Although it is well established that
not every tumor will eventually metastasize, it is less clear whether
primary tumors acquire genetic alterations in a stochastic process
at a late stage, which make them invasive, or whether genetic
alterations acquired early in the process of tumor development
drive primary tumor growth and determine whether this tumor is
going to be metastatic. To address this issue, we tested genes
identified in a large-scale comparative genomic hybridization anal-
ysis of primary tumor for their ability to confer metastatic prop-
erties on a cancer cell. We identified amplification of theACK1gene
in primary tumors, which correlates with poor prognosis. We
further show that overexpression of Ack1 in cancer cell lines can
increase the invasive phenotype of these cells both in vitro and in
vivo and leads to increased mortality in a mouse model of metas-
tasis. Biochemical studies show that Ack1 is involved in extracel-
lular matrix-induced integrin signaling, ultimately activating sig-
naling processes like the activation of the small GTPase Rac. Taken
together, this study supports a theory from Bernards and
Weinberg [Bernards, R. & Weinberg, R. A. (2002) Nature 418, 823],
which postulates that the tendency to metastasize is largely
predetermined.
cancer  metastasis
Despite increasing detailed molecular understanding of pro-cesses that underlie metastatic spread of cancers, such as
increased cellular motility and invasiveness, the genetic alterations
responsible for enabling human tumor metastasis are poorly un-
derstood. The prevailing view is that cancer cells acquire mutations
late in tumor development that confer metastatic properties (1, 2),
but experimental evidence of genes that are specifically mutated in
human metastatic tumors is rare. In fact, comparative genomic
hybridization (CGH) analysis of several different human tumor
types has revealed a high degree of concordance between matched
primary and metastatic tumors (3, 4). Both gene expression pro-
filing and CGH analysis of primary tumors can predict metastasis
(5, 6). A hypothesis has been proposed that metastasis is not caused
by acquisition of new genetic abnormalities as previously thought
(1, 2) but is predetermined by the specific genetic alterations that
cancer cells acquire during primary tumor growth (7).
Here, we report the identification of an acquired genetic alter-
ation in primary human tumors that fulfils this prediction. The gene
encoding the non-receptor tyrosine kinase Ack1 (activated cdc42-
associated kinase) is present within a small amplicon at 3q29 that
can be found in human tumors of several tissue types. Copy number
gain of theACK1 gene as well as overexpression ofAck1mRNAare
most pronounced in advanced-stage primary tumors andmetastatic
tumors and rare in early-stage tumors, suggesting that primary
tumors harboring genetic alterations like gene amplification that
lead to Ack1 overexpression are predisposed to becomemetastatic.
Ack1 was originally identified as a cdc42-interacting protein, and
it was suggested to be a cdc42 effector (8). An Ack isoform termed
Ack2 was identified in a bovine cDNA library (9), but according to
the literature and database searches, other species, includingmouse
and human, have only one Ack gene and protein (Ack1).
In a melanoma cell line, Ack1 was shown to be involved in
chondroitin sulfate proteoglycan mediated cell spreading (10).
Several reports studying overexpressed Ack1 in nontransformed
cell lines in vitro present evidence for an important role of Ack1 in
the transduction of Rascdc42 signals (11–14), and very recently it
was suggested that Ack1 activity is required for the survival of
v-Ras-transformed murine fibroblasts (15). Despite these findings,
the in vivo consequences of Ack1 deregulation in the context of
cancer remain unclear.
We were not able to identify a strong effect of Ack1 modulation
on the growth of human cancer cell lines, but we found Ack1 to be
involved in the process of metastasis in vitro and in vivo. In cancer
cell lines of epithelial origin, its overexpression enhances cellular
motility, invasiveness, and the ability to metastasize to the lung,
resulting in increased mortality. We also show that ligand stimula-
tion of 31-integrin, a signaling process that promotes metastasis,
leads to activation of Ack1, and that Ack1 enhances p130Cas
phosphorylation and activation of Rac, two other signaling mole-
cules previously linked to metastasis.
Materials and Methods
Materials. Human tumor samples (containing 50% tumor cells)
were obtained from theCooperativeHumanTissueNetwork,Duke
University, the University of Michigan, Asterand Co., and Ardais
Co. Sequence-verified human cDNA clones (46,656) were pur-
chased from Research Genetics (Huntsville, AL). Antibodies
against the following proteins were used: Ack1 [rabbit polyclonal
antibody (pAb) CVQL raised against Ack1 peptide (REEEKL-
KAEEIRIKGKYNISSEDYRQ)], phosphotyrosine [mAb 4G10
(PY); Upstate Biotechnology, Lake Placid, NY], integrin antibod-
ies [mAbs, 3-(P1B5, ASC-1), 1-(21C8, 6S6); Chemicon],
p130Cas, E- and N-cadherin, fibronectin, and -, -, and -catenin
(mAbs; BD Transduction Laboratories), and -smooth muscle
actin (ascitic fluid; Sigma). ACK1 was PCR-amplified from placen-
tal cDNA (Invitrogen) by using primers designed from the pub-
lished sequence, cloned into a retroviral vector, pLPC, and se-
quenced. Our ACK1 cDNA sequence is identical to the underlying
genomic sequence in the human assembly but differs in a few
nucleotides from the original cDNA sequence (8). The cell lines
MDA-MB-231 and 4T1 were obtained from American Type Cul-
ture Collection, human mammary epithelial cells (HMEC) were
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obtained from Cambrex, and each was cultured according to the
supplier’s protocol. Extracellular matrix-coated culture dishes and
tumor-invasion chambers were from BD Biosciences.
Western Immunoblotting, Adhesion, and Invasion Assays. Western
analysis and invasion assays were performed as described in ref. 16.
Briefly, cells were kept in suspension for 4 h and plated onto either
laminin or collagen IV plates for 30 min. Cells were pretreated for
30 min with 20 gml stimulatory-3-(P1B5), 1-(21C8) or inhib-
itory-3-(ASC-1), 1-(6S6)-integrin antibodies before plating. For
adhesion assays, 2  104 cells were plated on laminin-precoated
96-well plates, incubated for 1 h, and washed three times with PBS.
Adherent cells were quantified by using Cell-Titer-Glo Reagent
(Promega) according to the supplier’s protocol. For invasion assays,
5  104 (4T1) or 5  105 cells were plated on Matrigel-precoated
FluoroBlok (BD Biosciences) invasion chambers. Conditioned
NIH 3T3 medium was used as a chemoattractant. After 16 h (4T1)
or 24 h (HMEC) of incubation, invaded cells were labeled with
Calcein-AM, and fluorescence was read in a plate reader at
530590 nm.
Viral Production and Infection of Target Cells. The production of
amphotropic retroviruses and infection of target cells was described
in ref. 16. The 4T1 cells were selected with 12 gml puromycin.
MDA-MB-231 and HMEC were selected in 2 gml puromycin.
In Vivo Metastasis Assays, Moribundancy Study, and Isolation of
Tumor Cells from Blood and Lung.The femaleBALBcmice used for
this study were between 6 and 8 weeks old and were obtained from
Harlan. Theywere housed inmicrofilter cages. All cages, water, and
food were autoclaved before use. The cages were maintained in an
air-conditioned and light-controlled (12 hday) room. Mice and
mammary gland injection and isolation of tumor cells from blood
and lung was performed as described in ref. 17. The experiment was
performed twice with 10 and 30 mice per group, respectively.
For the moribundancy study (50 mice per group), the primary
tumors were surgically removed when they reached a size between
1,000 and 1,500 mm3 according to established protocols (18). All
animals were monitored until they were moribund, at which point
they were killed. Animals that died within 24 h of the surgical
procedure were removed from the analysis (six animals per group).
All of the mice in this study were maintained in an animal facility
accredited by the Institutional Animal Care and Use Committee of
Amgen San Francisco.
Genomic Microarray Hybridizations. Genomic DNA microarray hy-
bridizations were carried out essentially as described in ref. 19
except that instead of hybridizing in 3.4 SSC0.3% SDS at 65°C,
we hybridized in 25% formamide5 SSC0.1% SDS at 59°C.
Microarrays were scanned with a GenePix 4000 scanner (Axon
Instruments, Union City, CA) and analyzed with GENEPIX PRO 3.0
Fig. 1. ACK1 is amplified in chromosome 3, overexpressed, and associated with poor prognosis in human tumors. (a) Genomic microarray analysis of relative
DNA copy number along chromosome (Chr.) 3 in several tumor types. (b) DNA copy number for eight tumors (two hormone-refractory prostate tumors, red and
blue asterisks; two ovarian tumors, solid blue and green quadrilaterals; two esophageal tumors, blue and red dashes; a lung tumor, solid green circles; and a
pancreatic tumor, open magenta circles). DNA copy number is plotted in megabase pairs against their nucleotide position in chromosome 3 (http:
genome.ucsc.edu; April 2003 freeze). The data shown are from single DNA TaqMan assays [each with duplicate measurements with coefficient of variation (CV)
5%], and each assay was performed three times with an average CV10%. (c) CorrespondingACK1DNA and RNA values for lung, ovarian, and prostate tumors
as determined by QPCR, with relative RNA levels on a log scale. Ack1 RNA was measured by quantitative QPCR in normal prostate tissues, primary prostate tumors,
and hormone-refractory prostate tumors (d) (values50 times are shown as 50); and normal lung tissues, stage 1 and 2 lung tumors, and stage 3 and 4 tumors
(e). The values were normalized to the average value obtained with five corresponding normal tissue samples.
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software. The chromosomal position of 98% of the cDNAs was
determined by BLAT analysis (http:genome.ucsc.educgi-bin
hgBlat). A PERL programwas used to assign chromosomal locations
to the cDNA fluorescence ratios (corresponding to the amount of
tumorDNA relative to normal DNA) that were then averaged over
a window of five chromosomally contiguous cDNAs. The resultant
data were converted into chromosomal plots by using SPLUS (In-
sightful, Seattle).
Quantitative Real-Time PCR (QPCR).Quantification of human cells in
mice lungs is described in ref. 20. Fluorogenic TaqMan QPCR
probes were designed by using the PRIMER EXPRESS software
(Applied Biosystems). DNA copy number was quantified by using
the Applied Biosystems 7700 or 7900 sequence detection system
(Applied Biosystems). mRNA levels of ACK1 in tumors and in
corresponding normal tissues (Clontech) were determined by per-
forming quantitative PCR with fluorogenic TaqMan probes di-
rectly after reverse-transcriptase reactions. Absolute mRNA levels
for Ack1 were within 50% for 3–10 different samples of each of the
15 normal tissue types examined. -actin was used as a reference
probe.
Results and Discussion
The ACK1 Gene Is Amplified and Ack1 mRNA Is Overexpressed in
Human Tumors. Based on the observation that both gene expression
profiling and CGH analysis of primary tumors can predict metas-
tasis (5, 6), we initiated a search for specific, acquired genetic
alterations and the resulting changes in gene expression in primary
tumors that can confer metastatic properties. To identify highly
localized regions of tumor-specific DNA amplification, and to
overcome the low resolution associated with previous studies, at
least 30 advanced-stage tumors from each of breast, esophageal,
lung, ovarian, pancreatic, and prostate cancer types were surveyed
by array CGH using the 46K set of sequence-verified cDNA clones.
We focused the analysis on chromosome 3, because previous
work on chromosomal alterations in primary tumors found that 3q
gain is associated with recurrence in prostate tumors and is a strong
predictor of metastatic relapse in a node-negative breast cancer
CGH study (6, 21). Although we detected relatively frequent
amplification of broad regions of DNA on chromosome 3q, a few
tumors showed amuch tighter area of increasedDNAcopy number
2 Mb distal to the telomere at 3q (Fig. 1a). To determine the
amplicon boundaries of this smaller region, we applied quantitative
real-time PCR (QPCR) analysis to a panel of tumors harboring
amplification to measure the DNA copy number at points distrib-
uted throughout the region. This analysis restricted the common
area of amplification to a 135-kbp segment that contained only two
RefSeq genes, a part of MUC4 (a single noncoding exon) and the
complete coding sequence for ACK1 (Fig. 1b). Furthermore, this
high-resolution analysis indicated that ACK1 was within a focal
point of higher level amplification in tumors that by microarray
analysis contained a broad region of 3q gain (data not shown).
QPCR analysis of mRNA from tumor samples with Ack1-
specific probe sets confirmed that ACK1 amplification resulted in
elevated Ack1 RNA levels, and moreover a significant percentage
of tumors overexpress ACK1 in the absence of gene amplification,
showing that gene amplification is not the only way to overexpress
and presumably activate Ack1 (Fig. 1c). The highest frequencies of
ACK1 amplification in primary tumors (9% to 14%) were detected
in ovarian and lung types, respectively (see Fig. 5a, which is
published as supporting information on the PNAS web site); both
of these tumor types have been previously reported to have
frequent gain of 3q as judged by CGH (22).
Ack1 overexpression is frequent in aggressive lung tumors, with
20 of 47 later stage lung tumors exhibiting elevated ACK1 RNA
levels (6- to 35-fold) (Fig. 1d), whereas only 2 of 33 early stage
tumors displayed overexpression of ACK1 (6- to 10-fold). A similar
association with tumor stage was observed in prostate cancer.
Althoughwedid not have access to late-stage primary tumors,Ack1
overexpression was frequently found in metastatic, hormone-
refractory prostate tumors (10 of 13 samples displayed 5- to
100-fold overexpression) but rarely in early-stage, primary pros-
Fig. 2. Ack1 overexpression in tumor cells enhances metastasis and mortality in
vivo. (a) Experimental metastasis assay with 231-pLPC and 231-Ack1 cells after 60
days. Human cells in mouse lungs were quantified by applying ALU-QPCR as
described in ref. 20. Samples have been analyzed in quadruplicate and normal-
ized against normal lung; each bar represents the results from an individual lung.
(b and c) Colony formation of 4T1 cells isolated from lungs (b) or blood (c) of
BALBc mice 28 days after implantation. Tumor cells were cultivated for 21 days
in vitro under selective conditions before colonies were fixed, stained, and
counted. The experiment was performed twice with 10 and 30 mice per group
(data shown are average of 30 individual samples). (d) Kaplan–Meier survival
analysis of BALBc mice inoculated with 4T1 cells overexpressing Ack1 or vector
control. The primary tumor was removed when it reached a volume of 1,000–
1,500 mm3, and the animals were monitored until they were moribund (44
animals per group). The experiment was stopped when all animals in the Ack1
group died and statistical significance was reached (P 0.0001; paired t test).
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tate tumors (1 of 53 samples; Fig. 1e). Three of 13 metastatic
hormone-refractory prostate tumors harbored low-level ACK1
amplification, whereas none of 64 primary prostate tumors showed
amplification, although the relatively low tumor cellularity of pri-
mary prostate tumor samples may have obscured low-level ampli-
fication. The pronounced overexpression ofACK1 in advanced lung
and prostate tumors indicates an association with cancer progres-
sion and suggests that it could be a gene underlying the association
of 3q gain with poor prognosis (21).
Ack1 Overexpression Can Lead to Increased Metastasis in Vivo. The
results described above establish that ACK1 is genomically altered
in aggressive tumors and a candidate for a genetic determinant of
metastasis. To study the functional consequences of this genomic
alteration, we forcibly overexpressed ACK1 in a human breast
cancer cell line,MDA-MB-231, by retroviral infection. This cell line
has been used extensively to model metastatic processes and has
normal levels of endogenous ACK1 gene dosage and expression
(data not shown). We injected pools of MDA-MB-231 cells over-
expressing Ack1 (231-Ack1) or empty-vector (231-pLPC) intrave-
nously into immunocompromised mice. After 60 days, lungs of the
mice were harvested, and we measured the tumor burden in the
lungs by QPCR detection of human-specific DNA sequences (20).
When compared with the control group, we observed a dramatic
increase of tumor cells in the lungs in the Ack1-overexpressing
group, demonstrating that overexpression of Ack1 can enhance
metastasis (Fig. 2a). To explore the generality of this finding, we
repeated this analysis using an alternate model system, the 4T1
mouse mammary tumor model (17). Ack1-overexpressing (4T1-
Ack1) and control (4T1-pLPC) cells were implanted into the
mammary fat pad of syngeneic, female BALBc mice. Tumor
volume measurements over the course of the experiment showed
that primary tumor growth was not altered by overexpression of
Ack1 (Fig. 5b). After 28 days, we harvested the lungs and propa-
gated the tumor cells in vitro by cultivating them in selective media
that only allowed the transfected cells to survive. As shown in Fig.
2b, after 21 days, colony formation of 4T1-Ack1 cells was markedly
elevated (84  4 colonies), compared with 4T1-pLPC cells (43 
Fig. 3. Ack1 overexpression enhances invasiveness in vitro, phenotypical changes, and enhanced motility in HMEC and 4T1 cells. (a) HMEC-pLPC or HMEC-Ack1
cells were plated at low-density and photographed after 3 days. A representative photograph is shown. (b) Expression pattern of epithelial-marker (Left),
mesenchymal-marker proteins (Right), and Ack1 expression in HMEC-pLPC and HMEC-Ack1 cells. (c) Matrigel-invasion assay with HMEC-pLPC or HMEC-Ack1 and
4T1-pLPC or 4T1-Ack1 cells after 24 h. The experiment was performed twice in octaduplicates (P  0.001; Student’s t test). Invasiveness has been quantified as
described in the legend of Fig. 5.
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2 colonies). This result confirms thatAck1 overexpression is leading
to a higher tumor burden in the lung.
We used the 4T1 system, which mimics human tumor metastasis
in that the tumor cells need to escape froma primary site, to explore
which step in the in vivo process of metastasis was being affected by
Ack1 overexpression. To detect the presence of circulating cancer
cells in vivo, blood samples from mice carrying primary 4T1-pLPC
and 4T1-Ack1 tumors were collected and propagated in the pres-
ence of puromycin. Both groups showed similar colony formation,
indicating that Ack1 has no effect on escape from the primary
tumor, entry into the blood system, or survival of the cells in the
blood system (Fig. 2c). This finding implies that Ack1 affects the
ability of circulating tumor cells to escape the blood system andor
invade and colonize the lung.
Finally, we studied the effect of the Ack1-dependent, increased
metastasis on survival. Like in the previous studies, Ack1-
overexpressing (4T1-Ack1) and control (4T1-pLPC) cells were
implanted into the mammary fat pad of syngeneic, female BALBc
mice, but in this study the primary tumors were surgically removed
when they reached a size between 1,000 and 1,500 mm3. Animals
that died within 24 h of the surgical procedure were removed from
the analysis. All animals were monitored until they were moribund,
at which point they were killed (44 mice per group). After 50 days,
all animals in the Ack1 group were dead, whereas in the control
group 29% of the animals were still alive (Fig. 2d).
Ack1 Overexpression Induces Metastatic Phenotypes in Vitro. To
further evaluate the proposed metastatic role for Ack1, we exam-
ined its effects on in vitro correlates of metastasis: adhesion,
motility, epithelial-mesenchymal transition, and invasion. Ack1
overexpression did not affect the adhesiveness of MDA-MB-231
cells to either laminin- or collagen IV-coated plates or TNF--
activated human umbilical vein endothelial cells significantly (Fig.
5c and d). However, we did observe an effect of Ack1 overexpres-
sion onmotility as determined by wound-healing assays in 4T1 cells.
Compared with the control cells 4T1-pLPC, 4T1-Ack1 cells had
significantly enhanced motility as judged by this assay (Fig. 5e).
Because increased motility of epithelial cells often results from a
cellular transition termed the epithelial-mesenchymal transition
(EMT) (23), we examined whether Ack1 overexpression could
induce EMT in primary HMEC. Ack1 overexpression changed the
cobblestone-like appearance and extensive cell–cell contacts of
HMEC with a spindle-like, fibroblastic morphology with far fewer
cell–cell contacts (Fig. 3a). We observed a large increase in the
mesenchymal markers fibronectin and -smooth-muscle actin but
no dramatic decrease in the epithelial-marker proteins (Fig. 3b).
Although Ack1 overexpression alone does not induce all of the
stereotypical changes associatedwithEMT (23), it might contribute
to this transformation. We then examined effects of Ack1 overex-
pression on invasiveness in both HMEC and 4T1 cells and in both
cases observed a 2-fold increase in the Matrigel-invasion assays
(Fig. 3c).
Ack1 Is Involved in Integrin Signaling. To elucidate the molecular
mechanism by which Ack1 contributes to the process of metastasis,
we examined whether Ack1 affected the function of proteins that
have clearly established roles in cellular processes that underlie the
transition from primary to metastatic cancer. In this context,
integrins are essential signaling molecules for cell attachment,
cell-cycle progression, apoptosis, and cell migration in normal and
transformed cells (24), and integrin signals play a crucial role in the
progression from tumor growth to metastasis (25, 26). In the tumor
microenvironment, laminin and collagen IV are the most common
extracellular matrix (ECM) proteins, representing over 70% of all
possible integrin ligations (25). Therefore, we investigated the
activation of Ack1 through these particular ECM proteins. We
plated MDA-MB-231 on either laminin- or collagen IV-coated
plates and measured tyrosine phosphorylation of Ack1 (Fig. 4a).
Fig. 4. Ack1 is tyrosine-phosphorylated upon 31-ligation, associates with
p130Cas, and enhances GTP loading of Rac in the breast cancer cell line
MDA-MB-231. (a) Tyrosine phosphorylation of Ack1 displays different kinetics
when plated onto laminin (LN) or collagen IV (CollIV) plates in MDA-MB-231
cells. Please note that in Fig. 1a, lane 2 corresponds to cells kept in suspension.
(b) Tyrosine phosphorylation of Ack1 depends on 31-integrin ligation.
MDA-MB-231 cells were pretreated for 30 min with either stimulatory ()- or
inhibitory ()-integrin antibodies before plating onto LN or plastic (PL). (c)
Forced expression of Ack1 increases tyrosine phosphorylation of p130Cas
upon LN stimulation in 231-Ack1 cells. (d) Ack1 associates with p130Cas upon
LN stimulation in parental MDA-MB-231 cells. (e) GST-Pak1B pull down with
231-pLPC and 231-Ack1 cells after laminin stimulation. Cell lysates were
subjected to immunoprecipitation (IP) with anti-Ack1 (Ack1) (a–d topmost
panel) or p130Cas (c Middle). Tyrosine phosphorylation was analyzed by
Western blotting (WB) with monoclonal antiphosphotyrosine antibody (-
PY). Loading of proteins and coprecipitation of p130Cas was controlled by
reblotting with -Ack1 and -p130Cas. GTP-loaded Rac was analyzed by
Western blotting with anti-Rac antibody (-Rac). Arrows indicate the detected
proteins.
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Compared with cells in suspension (or cells plated on uncoated
tissue culture vessels; data not shown), Ack1 tyrosine phosphory-
lation was dramatically increased when cells were plated on either
ECM substrate, suggesting that integrin ligation is involved in its
activation. To confirm this and rule out othermechanisms activated
in the attachment process, we stimulated the suspension breast
cancer cell line DU-4475 with soluble laminin and observed again
an increase in tyrosine-phosphorylated Ack1 (Fig. 5f). To deter-
minewhich integrinswere involved,weused integrin antibodies that
were directed to the 3- and 1-subunits of the major laminin
receptor. We either incubated the cells with stimulatory 3 and 1
antibodies in suspension or preincubated the cells with inhibitory
3- and 1-integrin antibodies before plating onto laminin-coated
plates (Fig. 4b). The 3- and 1-integrin stimulatory antibodies
enhanced tyrosine phosphorylation ofAck1, whereas inhibitory3-
and 1-integrin antibodies reduced laminin-mediated activation of
Ack1. This establishes that 3- and 1-integrin are at least partially
responsible forAck1 activation. Both laminin and collagen IV share
1-integrin as a major heterodimerization partner for various
-integrins, and although our data show that 3- and 1-integrins
can activate Ack1 in this experimental setting, the involvement of
other - or -integrins cannot be excluded. Interestingly, recent
studies have demonstrated that 31-integrin facilitates lung me-
tastases (25) and together with our data suggest that 31-induced
Ack1 tyrosine kinase signaling contributes to the metastatic
process.
It was previously reported that the invasion of melanoma cells
can be induced by 41-ligation and subsequent tyrosyl-
phosphorylated p130Cas, an important component of the integrin
network, involved in cytoskeletal regulation and cell adhesion (10,
27). Thus, we tested whether upon laminin stimulation Ack1
interactedwith and enhanced tyrosine phosphorylation of p130Cas.
231-Ack1 and 231-pLPC cells were plated onto laminin plates, and
Ack1 or p130Cas was immunoprecipitated (Fig. 4c). As expected,
tyrosine phosphorylation of Ack1 and p130Cas was enhanced upon
plating the cells onto laminin, but the phosphorylation of p130Cas
was greater in cells overexpressing Ack1. This finding suggests that
Ack1 can mediate tyrosine phosphorylation of p130Cas. To sub-
stantiate our finding, immunoprecipitates of Ack1were analyzed by
Western blotting with anti-p130Cas. And indeed, upon laminin
stimulation Ack1 interacts with p130Cas, which coincides with
increased tyrosine phosphorylation of p130Cas (Fig. 4d). Another
important step in integrin signaling is the activation of Rac (27).
BecauseCdc42 andRac1 induce integrin-mediated cellmotility and
invasiveness and Rac is highly expressed in aggressive breast cancer
(28), we next studied the Ack1-dependent activation of Rac in
MDA-MB-231 cells. To discriminate between inactive-GDP- and
active-GTP-bound Rac, pull-down assays with the Cdc42Rac
interacting domain of Pak1B (GST-Pak1B) were performed. Rac
was constitutively bound to GTP in 231-Ack1 cells, whereas in
231-pLPC cells activation of Rac was inducible upon laminin
stimulation (Fig. 4e).
Previous work suggests that laminin-5-activated 31-integrins
can facilitate lung colonization of tumor cells, by promoting their
adhesion to laminin-5 on the vasculature (25, 29). Our data indicate
that 31-ligation activates Ack1, leading to increased Rac activity
and cell motility. These results establish that, upon overexpression
of Ack1, tumor cells can acquire a more invasive phenotype. In vivo
studies suggest that enhancedAck1 activity contributes significantly
to the extravasation process, thereby efficiently completing the
metastatic cascade and increasing the mortality rate.
Surprisingly, we did not observe an effect of Ack1 overexpression
on the growth of the primary tumor in the 4T1 model. Using
standard transformation assays like growth in soft agar or growth
or survival in low serum, we did not identify a pronounced effect
of Ack1 overexpression in a set of human cancer cell lines (data not
shown). Nevertheless, we suspect that there is a role for Ack1 in
biological aspects of cancer progression that underlies the selection
for its amplification in premetastatic lesions. This role may be as a
modifier of the oncogenic activity of other genetic events that occur
in premetastatic lesions. In fact, a recent report provides evidence
that Ack1 activity supports the survival of Ras transformed murine
fibroblasts (15).
Taken together, these findings confirm the prediction that cer-
tain primary tumors have genetic alterations that directly influence
metastasis (7). Although early work with rodent fibroblasts sug-
gested that activatingmutations inRas oncogenes were ametastatic
determinant, subsequent analysis of different cell types including
human cells failed to substantiate this link (30). Our data suggest
that ACK1 might be one of the first reported examples of an
amplified gene as a metastatic determinant in primary tumors, and
the properties described here forAck1make it a potential target for
developing anti-metastatic cancer therapeutics.
We thank Martin Broome for many helpful discussions.
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